Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461380 | 0.91 | MAPK1 (0.32) | DGAT1 | |
| SCHEMBL1108608 | 0.82 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL3635556 | 0.82 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL5214265 | 0.81 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL1258041 | 0.80 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL3033883 | 0.78 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL3028184 | 0.78 | MLKL (0.34) | DGAT1 | |
| SCHEMBL1258029 | 0.77 | F11 (0.32) | DGAT1 | |
| SCHEMBL3635834 | 0.77 | — | — | |
| SCHEMBL3636766 | 0.74 | NPC1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| EP-2483246-B1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9221763-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221763-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| US-20110218224-A1 | CRYSTALLINE ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID AND METHODS FOR PREPARING THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-09-08 | — | — | US | disclosed |
| US-8013005-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110092551-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110077411-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-03-31 | — | — | US | disclosed |
| US-7879896-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7855221-B2 | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid | THERAVANCE, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100099134-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100081697-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-01 | — | — | US | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092551-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | DGAT1 4776/4885 |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | DGAT1 4806/4885 |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | DGAT1 4776/4885 |
| US-20110077411-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | CYP4F3, CYP1B1, BMI1 | DGAT1 4809/4885 |
| US-20100081697-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | FFAR1, FFAR3, FFAR2 | DGAT1 3137/4885 |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | AGTR1, AGTR2, REN | DGAT1 4790/4885 |
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | DGAT1 1163/4885 |
| US-20110218224-A1 | CRYSTALLINE ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID AND METHODS FOR PREPARING THEREOF | REN, CYP4A11, MCCC2 | DGAT1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.